POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (6.18.2021, 11:43am CEST, WHO):   U.S. 11,767    India 67,208    Brazil 95,367    France 2,865    Turkey 6,221    Russia 14,057    The United Kingdom 8,808    Italy 1,400    Argentina 25,878    Columbia 27,827    Spain 1,922    Germany 1,330    Iran 10,291    Mexico 3,789    Ukraine 1,188    Peru 7,713    Indonesia 12,624    South Africa 13,246    The Netherlands 1,040    Chile 6,670    Canada 1,053    Philippines 6,637    Iraq 5,189    Pakistan 1,119    Portugal 1,350    Bangladesh 3,840    Japan 1,560    Malaysia 5,738    Nepal 1,768    United Arab Emirates 2,167    Saudi Arabia 1,309    Ecuador 1,161    Bolivia 2,836    Paraguay 2,612    Panama 1,048    Tunisia 2,379    Costa Rica 1,845    Uruguay 2,900    Kuwait 1,646    Guatemala 1,725    Venezuela 1,341    Oman 2,015    Sri Lanka 2,372    Thailand 3,129    Cuba 1,418    Zambia 3,026    Afghanistan 2,203    Mongolia 2,642    Uganda 1,110    China 198    Singapore 27    New Zealand 1    Australia 11    South Korea 507   

UK funded Imperial College coronavirus vaccine moves into first human trials

Christian Fernsby |
Clinical researchers will begin human trials of a new coronavirus vaccine developed by researchers at Imperial College London.

Article continues below




Beginning this week, the study will be the first time the vaccine has been trialled in humans and will test whether it is well-tolerated and produces an effective immune response against coronavirus.

This latest milestone follows £41 million in government funding towards the development of Imperial College London’s vaccine. A further £5 million of philanthropic gifts, including from hundreds of members of the public, has accelerated the work. The trials will be the first test of a new self-amplifying RNA technology, which has the potential to revolutionise vaccine development and enable scientists to respond more quickly to emerging diseases.

The vaccine has undergone rigorous pre-clinical safety tests and has been shown to be safe and produced encouraging signs of an effective immune response in animal studies. Over the coming weeks, 300 healthy participants will receive two doses of the vaccine.

Many traditional vaccines are based on a weakened or modified form of virus, or parts of it, but the Imperial vaccine is based on a new approach. It uses synthetic strands of genetic code (called RNA), based on the virus’s genetic material.


What to read next

3-in-1 vaccine against traveler's diarrhea
Candidate Ebola vaccine still effective when highly diluted
FDA's Marks: It deeply concerns us when we see preventable diseases reemerging